Literature DB >> 30249526

METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition.

Wenfeng Hua1, Yuan Zhao2, Xiaohan Jin3, Danyang Yu2, Jing He4, Dan Xie5, Ping Duan6.   

Abstract

OBJECTIVE: As the most prevalent internal modification in mammalian messenger RNA, N6‑methyladenosine (m6A) plays an important role in posttranscriptional gene regulation. METTL3 is a key component of the m6A methyltransferase complex and has recently been shown to play important roles in cancer development and progression. The current study was aimed to explore the function and underlying mechanism of METTL3 in ovarian cancer.
METHODS: METTL3 expression was assessed by immunohistochemistry in 162 ovarian carcinoma patients. Stable cell lines with METTL3 gene overexpression or knockdown were established to investigate the function of METTL3 in ovarian cancer in vitro and in vivo.
RESULTS: METTL3 was frequently upregulated in ovarian carcinoma and that a high level of METTL3 was significantly associated with tumor grade (P = 0.001), pT status (P = 0.002), pN/pM status (P < 0.001), FIGO stage (P < 0.001), and overall survival rate (P < 0.001). Stable overexpression of METTL3 in the OVCAR3 and COV504 cell lines significantly increased cellular proliferation, focus formation, motility, invasion, and tumor formation in nude mice. Silencing METTL3 expression in the SKOV3 and HO-8910 cell lines with short hairpin RNA effectively inhibited its oncogenic function. Further study found that METTL3 promoted epithelial-mesenchymal transition (EMT) by upregulating the receptor tyrosine kinase AXL.
CONCLUSION: Our findings suggest that METTL3 plays very important oncogenic roles in ovarian carcinoma development and/or aggressiveness by stimulating AXL translation and EMT and that METTL3 may serve as a novel prognostic and/or therapeutic target of interest in ovarian cancer.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AXL; EMT; METTL3; N(6)‑methyladenosine; Ovarian cancer

Mesh:

Substances:

Year:  2018        PMID: 30249526     DOI: 10.1016/j.ygyno.2018.09.015

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  63 in total

Review 1.  Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective.

Authors:  Yang Yang; Shuo Li; Yujiao Wang; Yi Zhao; Qiu Li
Journal:  Signal Transduct Target Ther       Date:  2022-09-17

2.  Gene signature of m6A-related targets to predict prognosis and immunotherapy response in ovarian cancer.

Authors:  Wei Tan; Shiyi Liu; Zhimin Deng; Fangfang Dai; Mengqin Yuan; Wei Hu; Bingshu Li; Yanxiang Cheng
Journal:  J Cancer Res Clin Oncol       Date:  2022-09-01       Impact factor: 4.322

Review 3.  Crosstalk among m6A RNA methylation, hypoxia and metabolic reprogramming in TME: from immunosuppressive microenvironment to clinical application.

Authors:  Fusheng Zhang; Haiyang Liu; Meiqi Duan; Guang Wang; Zhenghou Zhang; Yutian Wang; Yiping Qian; Zhi Yang; Xiaofeng Jiang
Journal:  J Hematol Oncol       Date:  2022-07-06       Impact factor: 23.168

Review 4.  m6A Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer.

Authors:  Huilin Huang; Hengyou Weng; Jianjun Chen
Journal:  Cancer Cell       Date:  2020-03-16       Impact factor: 31.743

5.  Comprehensive Analysis of Expression Regulation for RNA m6A Regulators With Clinical Significance in Human Cancers.

Authors:  Xiaonan Liu; Pei Wang; Xufei Teng; Zhang Zhang; Shuhui Song
Journal:  Front Oncol       Date:  2021-02-23       Impact factor: 6.244

6.  METTL3-mediated maturation of miR-126-5p promotes ovarian cancer progression via PTEN-mediated PI3K/Akt/mTOR pathway.

Authors:  Xuehan Bi; Xiao Lv; Dajiang Liu; Hongtao Guo; Guang Yao; Lijuan Wang; Xiaolei Liang; Yongxiu Yang
Journal:  Cancer Gene Ther       Date:  2020-09-16       Impact factor: 5.987

7.  An N6-Methyladenosine-Related Gene Set Variation Score as a Prognostic Tool for Lung Adenocarcinoma.

Authors:  Huijuan Zhang; Jing Hu; Aina Liu; Huajun Qu; Fenge Jiang; Congcong Wang; Steven Mo; Ping Sun
Journal:  Front Cell Dev Biol       Date:  2021-07-08

8.  m6A RNA Methylation Regulators Elicit Malignant Progression and Predict Clinical Outcome in Hepatocellular Carcinoma.

Authors:  Wenli Li; Jun Liu; Zhanzhong Ma; Xiaofeng Zhai; Binbin Cheng; Hetong Zhao
Journal:  Dis Markers       Date:  2021-06-04       Impact factor: 3.434

9.  Hub Long Noncoding RNAs with m6A Modification for Signatures and Prognostic Values in Kidney Renal Clear Cell Carcinoma.

Authors:  Gaoteng Lin; Huadong Wang; Yuqi Wu; Keruo Wang; Gang Li
Journal:  Front Mol Biosci       Date:  2021-07-06

10.  Identification and validation of lncRNAs involved in m6A regulation for patients with ovarian cancer.

Authors:  Jianfeng Zheng; Jialu Guo; Benben Cao; Ying Zhou; Jinyi Tong
Journal:  Cancer Cell Int       Date:  2021-07-08       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.